FHI Clinical works with new partners to help mitigate effects of COVID-19

August 4, 2020

Tiziana Life Sciences, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announced that it has signed agreements with FHI Clinical and three additional providers to expedite clinical development of TZLS-501, a novel fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb), for the treatment of COVID-19 (SARS-CoV-2) patients.

Currently, FHI Clinical is collaborating with a team of regulatory and medical experts to help draft a protocol and drug development plan for upcoming pre-IND meetings. FHI Clinical also will provide full CRO services for the clinical study, expected to begin in Q1 2021. In this trial, TZLS-501 will be delivered as an aerosol directly to the lungs using a hand-held nebulizer.

Additional collaborators for this study include:

For more information, visit the Tiziana Life Sciences press release, and download our brochure to learn more about FHI Clinical’s COVID-19 research services.

news archive

Evaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study

September 7, 2022
The global ACTT-4 study, supported by FHI Clinical, evaluated baricitinib vs dexamethasone for adults hospitalized with COVID-19. This trial is the fourth and final stage in a series of phase 3, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy and safety of investigational therapeutic agents in hospitalized adults with laboratory-confirmed COVID-19.

Read more »

FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

February 8, 2022
FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO. With the acquisition, FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes the dominant service provider in sub-Saharan Africa.

Read more »

Share this post